Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
IntelGenx granted FDA Type A meeting related to RIZAPORT VersaFilm » 08:12
05/27/20
05/27
08:12
05/27/20
08:12
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

IntelGenx announced that…

IntelGenx announced that the U.S. Food & Drug Administration has granted the Company's request for a Type A meeting related to its RIZAPORT VersaFilm program. This meeting has been scheduled for June 10, 2020. On March 27, 2020, IntelGenx received a Complete Response Letter from the FDA regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT VersaFilm for the treatment of acute migraines. The CRL states that the FDA cannot approve the application in its present form. The Agency requested additional information, but no new bioequivalence study.

ShowHide Related Items >><<
IGXT IntelGenx
$0.00 /

+ (+0.00%)

IGXT IntelGenx
$0.00 /

+ (+0.00%)

Over a week ago
Hot Stocks
IntelGenx announces intention to amend convertible debentures » 08:40
05/12/20
05/12
08:40
05/12/20
08:40
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

IntelGenx Technologies…

IntelGenx Technologies announced that it is proposing to amend the terms of its 8.0% convertible unsecured subordinated debentures due June 30, 2020, originally issued on July 12, 2017 and August 8, 2017 (the "Debentures"), to extend the maturity date from June 30, 2020 to June 30, 2022 and reduce the conversion price from $1.35 to $0.50. The proposed amendments remain subject to approval of the TSX Venture Exchange and the holders of not less than 66 2/3% of the outstanding principal amount of the Debentures. An aggregate principal amount of $7,577,000 of Debentures remains outstanding as of the date hereof.

ShowHide Related Items >><<
IGXT IntelGenx
$0.00 /

+ (+0.00%)

IGXT IntelGenx
$0.00 /

+ (+0.00%)

Hot Stocks
IntelGenx expects to receive micro-processing license in April » 08:19
04/28/20
04/28
08:19
04/28/20
08:19
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

In response to investor…

In response to investor and media inquiries, IntelGenx Technologies provided an update regarding its micro-processing license application for its Montreal, Quebec facility that is currently being reviewed by Health Canada, in accordance with the Cannabis Act and Cannabis Regulations. "Based on recent conversations with Health Canada's Controlled Substances and Cannabis Branch, which is reviewing our application, we were expecting to receive our micro-processing license sometime in April," said Dr. Horst G. Zerbe, CEO of IntelGenx. "Health Canada has continued to review applications for new cannabis licenses and security-clearance applications during the COVID-19 pandemic, however, as its staff are operating remotely with a limited ability to perform certain functions, we have to accept the possibility of a delay."

Over a month ago
Hot Stocks
IntelGenx says BUENA clinical trial on temporary recruitment hold » 08:40
04/06/20
04/06
08:40
04/06/20
08:40
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

The company said,…

The company said, "IntelGenx has informed its employees, business partners and key stakeholders about immediate steps it has taken to manage potential health and business risks. These include proactive, precautionary measures, such as working from home when possible, freezing all non-essential travel, and switching to virtual sales and business meetings only, with the goal of keeping everyone safe. To help protect the well-being of its shareholders, Board and Management, the Company is also exploring the possibility of hosting its Annual General Meeting, which is scheduled to take place on Tuesday, May 12, 2020, via a virtual meeting instead of in-person. With respect to the impact of the COVID-19 pandemic on IntelGenx's product development programs, the most immediate change will be to subject enrolment in the ongoing Montelukast VersaFilm Phase 2a clinical trial in patients with mild to moderate Alzheimer's Disease. Because the target study population in the BUENA study is considered to be a higher risk group for severe illness from COVID-19, and out of concern for the health and safety of clinical trial staff, IntelGenx has informed HC that the study is on a temporary recruitment hold"

Hot Stocks
IntelGenx in talks to leave commercial production of RIZAPORT in Spain » 08:39
04/06/20
04/06
08:39
04/06/20
08:39
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

The company said,…

The company said, "As previously announced, the Company has established a partnership with Exeltis Healthcare for the commercialization of RIZAPORT in Spain and potentially other European countries. While IntelGenx was initially pursuing a manufacturing site change with the intent to supply the product from its Canadian manufacturing facility, it is now, together with Exeltis Healthcare, in advanced discussions with the originally listed contract manufacturing organization, which the Spanish marketing authorization lists as the approved manufacturer of the product, to leave the commercial production at its site."

Hot Stocks
IntelGenx plans to request meeting with FDA to discuss RIZAPORT CRL response » 08:38
04/06/20
04/06
08:38
04/06/20
08:38
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

The company said,…

The company said, "As previously announced, the March 2020 CRL states that the FDA could not approve the application in its present form. The Agency requested additional information, but no new bioequivalence study. IntelGenx plans to request a meeting with the FDA to discuss the CRL comments, with the goal of obtaining needed clarification and determining next steps."

Hot Stocks
IntelGenx says CEO Horst Zerbe will lead all product development, manufacturing » 08:37
04/06/20
04/06
08:37
04/06/20
08:37
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

The company said,…

The company said, "Pursuant to IntelGenx's revised business strategy, effective immediately, all product development and manufacturing functions, including R&D, regulatory affairs and operations, will be led by Dr. Zerbe, while CFO Godin will have overall responsibility for all business functions, including finance and business development. In addition, the Company's Board and management will immediately conduct a comprehensive review of all functions and reporting relationships in order to determine what, if any, management structural and personnel changes or additions are necessary to help ensure the Company's future success in these new circumstances."

Hot Stocks
IntelGenx initially cuts 10% of employee headcount  08:35
04/06/20
04/06
08:35
04/06/20
08:35
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

 
Hot Stocks
IntelGenx expects cash to fund planned operations into 4Q20 » 08:35
04/06/20
04/06
08:35
04/06/20
08:35
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

The company said,…

The company said, "As at December 31, 2019, IntelGenx had cash and short-term investments totalling $1.9 million, which the Company believes, together with the gross proceeds of C$8.2 million received from its February 2020 equity offering, are sufficient to fund planned operations into the fourth quarter of 2020. The Company has also taken immediate measures to reduce its burn rate by initially cutting 10% of its employee headcount, as well as decreasing non-essential expenses in all areas of its business. Additional cost reduction measures are being analysed in order to further extend the cash runway and may be implemented in the near future."

Hot Stocks
IntelGenx accelerates focus on short-term revenue generating opportunities » 08:34
04/06/20
04/06
08:34
04/06/20
08:34
IGXT

IntelGenx

$0.00 /

+ (+0.00%)

, TLRY

Tilray

$5.52 /

-0.53 (-8.76%)

The company said,…

The company said, "While IntelGenx's business development strategy will continue to focus on partnering its current product pipeline, which includes 10 pharmaceutical oral film product candidates, and pursuing potential oral thin film manufacturing opportunities, in light of recent unforeseeable developments, the Company will also accelerate its focus to pursue short-term revenue generating opportunities by expanding its pipeline to include additional products for which there is not an FDA or Health Canada approval requirement. These include nutraceutical films, for which IntelGenx is already in active discussions with potential partners. Finally, the Company will continue to work with HC to finalize the review of its micro-processing license application. Once the micro-processing license is received, which IntelGenx currently expects to occur in April 2020, the Company will be able to commence commercial production of cannabis-infused VersaFilm for its partner, Tilray, with product sales anticipated to begin as soon as practicable thereafter."

ShowHide Related Items >><<
IGXT IntelGenx
$0.00 /

+ (+0.00%)

TLRY Tilray
$5.52 /

-0.53 (-8.76%)

03/23/20 Roth Capital
Tilray price target lowered to $4 from $15 at Roth Capital
03/19/20 BofA
Tilray downgraded to Underperform from Neutral at BofA
03/16/20 Cantor Fitzgerald
Tilray price target lowered to $4.90 from $17.50 at Cantor Fitzgerald
03/04/20 GLJ Research
Tilray price target lowered to $0 from $5 at GLJ Research

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.